Dimerix (ASX:DXB) Other Long-Term Liabilities : A$10.26 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Dimerix Other Long-Term Liabilities?

Dimerix's other long-term liabilities for the quarter that ended in Dec. 2023 was A$10.26 Mil.

Dimerix's quarterly other long-term liabilities declined from Dec. 2022 (A$0.04 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$10.26 Mil).

Dimerix's annual other long-term liabilities declined from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$-0.00 Mil) but then increased from Jun. 2022 (A$-0.00 Mil) to Jun. 2023 (A$0.00 Mil).

Dimerix Other Long-Term Liabilities Historical Data

The historical data trend for Dimerix's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dimerix Other Long-Term Liabilities Chart

Dimerix Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Dimerix Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Dimerix Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Dimerix Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Dimerix's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Dimerix (ASX:DXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dimerix Ltd (ASX:DXB) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

425 Smith Street, Fitzroy, VIC, AUS, 3065

Website

https://www.dimerix.com

Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Dimerix (ASX:DXB) Headlines

No Headlines